Slide 1: Strategic Update and Financial Results for the Three Months Ended 30 September 2015
Strategic Update and Financial Results for the Three Months Ended 30 September 2015 December 2015 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, perf
Slide 3: Mesoblast - a global leader in cell based medicines
Mesoblast - a global leader in cell based medicines Disruptive technology platform: proprietary, allogeneic, “off-the-shelf” adult stem cells with predictable therapeutic properties Established late stage portfolio of distinct and advanced product candidates Targeted markets with high unmet medical
Slide 4: Successfully completed US listing with access to largest healthcare investor pool
Successfully completed US listing with access to world’s largest sophisticated healthcare investor pool and analysts Financing raised USD $63.5m (net proceeds) which significantly augmented existing cash reserves of USD $77.8m at 30 September 2015 Quarterly cash outflows expected to be reduced by ap
Slide 5: Product candidates target diseases with high unmet needs
Product candidates target diseases with high unmet needs Three Tier 1 Product Candidates in Phase 3 Programs Update
Slide 6: MSC-100-IV / TEMCELL HS Inj.: Product Launch Plans in aGVHD
MSC-100-IV / TEMCELL® HS Inj. : Product Launch Plans in aGVHD TEMCELL® HS Inj. is the first allogeneic stem cell product approved in Japan MSC-100-IV has the potential to be the first allogeneic stem cell product approved in US United States (MSC-100-IV): 2017 Potential FDA Approval Open-label Phase
Slide 7: MSC-100-IV / TEMCELL HS Inj. targeting pediatric and adult aGVHD patients
MSC-100-IV / TEMCELL® HS Inj. is targeting pediatric and adult patients with acute Graft Versus Host Disease (aGVHD) following allogeneic Bone Marrow Transplant (BMT). Gratwohl A et al Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Obs
Slide 8: 2016 - 2018 Tier Product Candidate Deliverables
2016 - 2018 Tier 1 Product Candidate Deliverables
Slide 9: Profit and Loss – Increased revenue and reduced expenditure
Profit and Loss – Increased revenue and reduced expenditureUSDm 3 months ending 30 Sep 2015 3 months ending 30 Sep 2014 Change % Revenue 7.5 7.0 0.5 7.8 Loss Before Income Tax 13.2 15.5 2.3 15.3 Revenue increased by 7% ($0.5m) vs comparative period in FY14: Milestone revenue of $3.5m has been recogn
Slide 10: Increased cash reserves and reduced operating cash burn
Increased cash reserves and reduced operating cash burnUSDm Recent US listing has added $63.5m (net proceeds) in November 2015 which significantly augmented existing cash reserves of $77.8m at 30 September 2015 Management’s focus and prioritization will result in approximately 20-25% reduction in qu
Slide 11: Company focused on delivery and communication of key corporate objectives
Company focused on delivery and communication of key corporate objectives Materially strengthened cash reserves post US listing and financing First royalties from TEMCELL product sales expected in Q1 2016 Focused allocation of resources on Tier 1 product candidates Quarterly cash outflows expected t
Slide 12: Appendix Historical Financial Results in USD
Appendix Historical Financial Results in USD
Slide 13: Retranslation of Historical Financials to USD
Retranslation of Historical Financials to USD As announced the reporting currency for Mesoblast has changed from Australian dollars to US dollars, commencing with the 2015/16 financial year The first reported results in US dollars are these results for the three months ended 30 September 2015 To ass
Slide 14: Profit and Loss – FY 2012 to FY2015
Profit and Loss – FY 2012 to FY2015USDm FY = Fiscal Years ended 30 June FY12 FY13 H1 14 H2 14 FY14 Q1 15 Q2 15 Q3 15 Q4 15 FY15 Revenue 39.6 29.3 12.4 11.0 23.4 7.0 4.4 4.2 4.2 19.8 Research & Development (37.8) (48.5) (23.2) (27.7) (50.9) (12.9) (17.8) (13.4) (18.5) (62.6) Manufacturing Commerciali
Slide 15: Cash Flows – FY 2012 to FY2015
Cash Flows – FY 2012 to FY2015USDm FY = Fiscal Years ended 30 June FY12 FY13 H1 14 H2 14 FY14 Q1 15 Q2 15 Q3 15 Q4 15 FY15 Milestone payment received - - - - - - 2.0 - - 2.0 R&D tax incentive received - - - 8.7 8.7 - - - 4.5 4.5 Payments to suppliers and employees (66.8) (69.8) (50.4) (47.0) (97.4)
Slide 16: Balance Sheets – FY 2012 to FY2015
Balance Sheets – FY 2012 to FY2015USDm FY = Fiscal Years ended 30 June FY12 FY13 H1 14 FY14 H1 15 FY15 Cash and cash equivalents 209.5 292.5 223.9 185.0 122.4 110.7 Current receivables 10.9 11.2 15.2 5.7 7.5 4.0 Other current assets 0.3 4.1 4.0 1.2 3.9 7.8 Current assets 220.7 307.8 243.1 191.9 133.